Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A + meningococcal group C + Haemophilus influenzae type b (conjugate) vaccine
- Development stage
- Unknown
- Lead developer
- Olymvax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The meningococcal group A + meningococcal group C + Haemophilus influenzae type b (conjugate) vaccine is a trivalent combination conjugate vaccine developed by Chengdu Olymvax Biotechnology (Olymvax). It is designed to provide simultaneous protection against *Neisseria meningitidis* serogroups A and C, as well as *Haemophilus influenzae* type b (Hib). The vaccine utilizes capsular polysaccharides from these pathogens conjugated to a carrier protein to elicit a robust T-cell-dependent immune response, which is particularly effective in infants and young children. It is indicated for the prevention of epidemic cerebrospinal meningitis and invasive Hib infections, including pneumonia, septicemia, and epiglottitis. As of 2024, the vaccine candidate has reached the NDA/BLA filing stage in China.
- Other names
- Group A+C Meningococcal and Haemophilus influenzae Type b (Conjugate) Combined VaccineAC-Hib conjugate vaccineAC-Hib vaccine
02
Targets
Neisseria meningitidis group C capsular polysaccharideNmA CPS (Neisseria meningitidis group A capsular polysaccharide)PRNP (Cellular Prion Protein)
Beyond the preview
Go deeper on meningococcal group A + meningococcal group C + Haemophilus influenzae type b (conjugate) vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A + meningococcal group C + Haemophilus influenzae type b (conjugate) vaccine.